




RealRate

REAL ESTATE 2015

HH Biotechnology Holdings CO Rank 37 of 56





RealRate

REAL ESTATE 2015

HH Biotechnology Holdings CO Rank 37 of 56

The relative strengths and weaknesses of HH Biotechnology Holdings CO are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of HH Biotechnology Holdings CO compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 16% points. The greatest weakness of HH Biotechnology Holdings CO is the variable Liabilities, Current, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is 46%, being 35% points below the market average of 81%.

Input Variable	Value in 1000 USD
Cost of Revenue	5,056
Depreciation and Amortization	24
General and Administrative Expense	4,405
Goodwill and Intangible Assets	0
Lease Income	5,822
Liabilities, Current	34,848
Liabilities, Long-term	0
Other Assets	53,984
Other Compr. Net Income	-562
Other Expenses	1,276
Other Liabilities	0
Other Net Income	625
Other Real Estate Investments, Net	0
Other Revenues	0
Real Estate Investment Property, Accumulated Depreciation	0
Real Estate Investment Property, at Cost	0

Output Variable	Value in 1000 USD
Real Estate Investments, Net	0
Liabilities	34,848
Assets	53,984
Revenues	5,822
Expenses	10,761
Stockholders Equity	19,137
Net Income	-4,313
Comprehensive Net Income	-4,634
BaseVar	56,145
ECR before LimitedLiability	15%
Economic Capital Ratio	46%